Back to Search
Start Over
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
- Source :
-
Blood cancer journal [Blood Cancer J] 2016 Jul 29; Vol. 6 (7), pp. e448. Date of Electronic Publication: 2016 Jul 29. - Publication Year :
- 2016
-
Abstract
- Competing Interests: Dr Stadtmauer has been a consultant for Celgene, Takeda and Amgen. Dr Stewart has received honoraria for consulting from Celgene. Dr Dreosti has received speaker honorarium from Janssen Pharmaceuticals and congress sponsorship from Janssen Pharmaceuticals. Dr Fonseca has received consulting fees from Celgene and Takeda. The remaining authors declare no conflict of interest.
- Subjects :
- Aged
Bortezomib adverse effects
Dexamethasone adverse effects
Female
Humans
Lenalidomide
Male
Middle Aged
Multiple Myeloma mortality
Multiple Myeloma pathology
Salvage Therapy
Survival Analysis
Thalidomide administration & dosage
Thalidomide adverse effects
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bortezomib administration & dosage
Consolidation Chemotherapy adverse effects
Consolidation Chemotherapy methods
Dexamethasone administration & dosage
Induction Chemotherapy methods
Multiple Myeloma drug therapy
Thalidomide analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 2044-5385
- Volume :
- 6
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Blood cancer journal
- Publication Type :
- Report
- Accession number :
- 27471864
- Full Text :
- https://doi.org/10.1038/bcj.2016.55